### Introduction

**Study design**

- **Objective:** To evaluate the effect of dosing timing (morning vs. evening) on the bronchodilating effect of once-daily IND/GLY/MF (325/86.5/50 mcg).
- **Methods:** Double-blind, placebo-controlled, randomized, multicenter study in patients with asthma.
- **Participants:** Men or women aged 18–75 years with a diagnosis of asthma and evening PEF < 70% of the best PEF value in the last 3 months.

### Methods

**Objectives**

- **Primary objective:** To determine the effect of dosing timing (morning vs. evening) on bronchodilating effect of IND/GLY/MF.
- **Secondary objectives:**
  - To evaluate the effect of dosing timing on treatment adherence.
  - To assess the effect of dosing timing on safety and tolerability.

### Results

**Safety and tolerability**

- **Adverse events:** No significant differences were observed in the incidence of adverse events between the morning and evening dosing groups.
- **Safety profile:** The overall safety profile of IND/GLY/MF was consistent with previous studies.

### Discussion

- **Clinical relevance:** IND/GLY/MF offers a convenient once-daily dosing regimen with a bronchodilating effect that is comparable to morning and evening dosing.

### Conclusions

- **Implications:** IND/GLY/MF dosing at any time of day is effective and safe in patients with asthma.

---

### Key exclusion criteria:

- Patients who had an exacerbation requiring systemic steroids, hospitalization, or both, within 30 days prior to the study.

### Figure 1: Study design

- **Timeline:**
  - **Screening:** 14 days
  - **Baseline:** 14 days
  - **Treatment Periods:** 14 days each
  - **Washout periods:** 21 days

### Figure 3: Mean morning PEF (L/min) over 24h

- **Key finding:** Morning PEF values were significantly higher after IND/GLY/MF dosing compared to placebo.

### Figure 4: Mean evening PEF (L/min) over 24h

- **Key finding:** Evening PEF values were significantly higher after IND/GLY/MF dosing compared to placebo.

---

**References**

- **Jutze Steiner:** Current concepts in respiratory medication: AstraZeneca's IND/GLY/MF is an extendable once-daily inhaler.
- **Novartis Pharma AG:** IND/GLY/MF: a convenient, once-daily treatment option for patients with asthma.
- **Dahlmann-Noberg:** Safety and tolerability of a novel triple combination ICS/LABA/FA: an option for patients with asthma.

---

**Acknowledgments**

- **Research funding:** The authors declare no conflicts of interest. The study was funded by AstraZeneca and Mennarini.

---

**Disclosure of commercial support and relevant financial interests**

The study was sponsored by AstraZeneca, Menarini, and Pohl-Boskamp. The authors report no conflicts of interest. The study was supported by grants from AstraZeneca and Menarini. The funder had no role in the study design, data collection, data analysis, or data interpretation.